VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Breast Oncology Program at the University of Michigan Cancer Center Ann Arbor. After his talk on the utility of genetic signatures to select adjuvant treatment he discussed his findings and conclusions with Oncology Time reporter Sarah Maxwell.
You may also like...
Oncology Times Broadcast News with the Audio Journal of Oncology 7 Jan, 2009 Breast Cancer: Further Support for Trastuzumab from Combined Analysis 30 Oct, 2005 Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer 15 Feb, 2008 Gender Disparity in Head and Neck Cancer Treatment and Outcomes 9 Jun, 2018
- Previous story New Strategies for Preventing ER-Negative Breast Cancer
- Next story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014